Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (1)
P 2 (2)

Trial Status

Recruiting2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04462406Phase 2Active Not Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

NCT05098210Phase 1Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT07155317Phase 2Recruiting

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Showing all 3 trials

Research Network

Activity Timeline